Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 4/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.33 |
| ▸ | AKT2 | P31751 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26478543 | 0.85 | OPRM1 (0.43) | OPRM1HTR2ATACR1HDAC1OPRD1 | |
| SCHEMBL24944261 | 0.85 | OPRM1 (0.46) | OPRM1HTR2ATACR1HDAC1OPRD1 | |
| SCHEMBL26413279 | 0.85 | OPRM1 (0.43) | OPRM1HTR2ATACR1HDAC1OPRD1 | |
| SCHEMBL24944864 | 0.85 | OPRM1 (0.46) | OPRM1HTR2ATACR1HDAC1OPRD1 | |
| SCHEMBL24944256 | 0.85 | OPRM1 (0.40) | OPRM1HTR2ATACR1CYP1A2CYP2D6 | |
| SCHEMBL26413660 | 0.84 | OPRM1 (0.42) | OPRM1HTR2ATACR1HDAC1OPRD1 | |
| SCHEMBL24944239 | 0.83 | OPRM1 (0.49) | OPRM1HTR2ATACR1HDAC1OPRD1 | |
| SCHEMBL26478563 | 0.82 | OPRM1 (0.46) | OPRM1HTR2ATACR1HDAC1OPRD1 | |
| SCHEMBL24944055 | 0.82 | OPRM1 (0.46) | OPRM1TACR1 | |
| SCHEMBL373568 | 0.81 | OPRM1 (0.50) | OPRM1HTR2ATACR1HDAC1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11644753-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-09 | — | — | US | disclosed |
| US-11644753-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-09 | — | — | US | disclosed |
| US-20230131303-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230131303-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230021453-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11644753-B2 | Resist composition and patterning process | HNRNPU, NSUN2, HNRNPR | OPRM1 775/4885HTR2A 3805/4885TACR1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.